Michael Steinmetz, Ph.D.

Michael Steinmetz, PhD, has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 24 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 1997. From 1986 to 1997, Dr. Steinmetz was an executive at Hoffmann-LaRoche where he held various positions including Vice President of Preclinical Research and Development, and Global Head of Biotechnology.

Dr. Steinmetz obtained his Ph.D. summa cum laude from the University of Munich and held positions at the California Institute of Technology and the Basel Institute for Immunology.

Dr. Steinmetz represents Clarus Ventures on the Board of Directors of ESBATech and Oxford Immunotec. In addition he is a member of the Board of Directors of Amphora, Biovitrum (STO:BVT), BioXell (SWX: BXLN), CGI Pharmaceuticals, ISB Accelerator, Macrogenics, Taigen ,and VLST Corp.

Previous directorships include Acorda (NASDAQ:ACOR), Arena (NASDAQ:ARNA), Atugen/SR Pharma (AIM:SPA), Caliper (NASDAQ:CALP), Coelecanth (acquired by Lexicon), GPC Biotech (FRK:GPC) and Epigenomics (FRK: ECX).